Important note: Information in this article was accurate in November 2009. The state of the art may have changed since the publication date.
Gemfibrozil significantly reduced by lopinavir/r
HIV Treat Bull - 2009 Nov/Dec;10(11/12): 29
This was an open label, single sequence study in 15 healthy volunteers comparing gemfibrozil pharmacokinetics parameters before and after two weeks of lopinavir/ritonavir (400/100 mg twice daily).
The GMR (90% CI) for gemfibrozil AUC after 14 days of lopinavir/ritonavir compared with base line was 0.59 (0.52 to 0.67) (P<0.001). GMR (90%CI) for gemfibrozil apparent oral clearance and Cmax were 1.69 (1.41 to 1.97) and 0.67 (0.49 to 0.86), respectively (P<0.0001 and P<0.01, respectively). There was no change in gemfibrozil half life.
It is not clear what the mechanism is for the reduction in the systemic exposure of gemfibrozil. However, clinicians treating HIV-infected patients for hypertriglyceridemia should be aware of this interaction.
Ref: Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr, 2009 Oct, 52(2): 235-239.
2009-11-10
IB2009-11-29
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in November 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.